{
    "clinical_study": {
        "@rank": "80636", 
        "arm_group": [
            {
                "arm_group_label": "Arm I (azacitidine, entinostat, chemotherapy)", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive azacitidine SC on days 1-6 and 8-10 and entinostat PO on days 3 and 10. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or progressive disease receive chemotherapy of the treating oncologist's choice comprising irinotecan hydrochloride IV on day 1, docetaxel IV on day 1, pemetrexed disodium IV on day 1, or gemcitabine hydrochloride IV on days 1 and 8. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity."
            }, 
            {
                "arm_group_label": "Arm II (azacitidine, entinostat, chemotherapy)", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive azacitidine PO on days 1-21 and entinostat PO on days 3 and 10. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or progressive disease receive chemotherapy of the treating oncologist's choice as in Arm A."
            }, 
            {
                "arm_group_label": "Arm III (chemotherapy)", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients receive chemotherapy of the treating oncologist's choice as in Arm A."
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized phase II trial studies how well azacitidine and entinostat before\n      chemotherapy in treating patients with advanced non-small cell lung cancer. Drugs used in\n      chemotherapy, such as azacitidine, irinotecan hydrochloride, gemcitabine hydrochloride,\n      docetaxel, and pemetrexed disodium, work in different ways to stop the growth of tumor\n      cells, either by killing the cells or by stopping them from dividing. Entinostat may stop\n      the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving\n      azacitidine and entinostat before chemotherapy may be an effective treatment for non-small\n      cell lung cancer."
        }, 
        "brief_title": "Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer", 
        "condition": [
            "Recurrent Non-small Cell Lung Cancer", 
            "Stage IIIA Non-small Cell Lung Cancer", 
            "Stage IIIB Non-small Cell Lung Cancer", 
            "Stage IV Non-small Cell Lung Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. Percentage of patients progression-free at 6 months from time of randomization.\n\n      SECONDARY OBJECTIVES:\n\n      I. Progression-free survival (PFS). II. Overall Survival (OS).\n\n      OUTLINE: Patients are randomized to 1 of 3 treatment arms.\n\n      ARM A: Patients receive azacitidine subcutaneously (SC) on days 1-6 and 8-10 and entinostat\n      orally (PO) on days 3 and 10. Treatment repeats every 28 days for 2 courses in the absence\n      of disease progression or unacceptable toxicity. Patients with stable or progressive disease\n      receive chemotherapy of the treating oncologist's choice comprising irinotecan hydrochloride\n      intravenously (IV) on day 1, docetaxel IV on day 1, pemetrexed disodium IV on day 1, or\n      gemcitabine hydrochloride IV on days 1 and 8. Treatment repeats every 21 days in the absence\n      of disease progression or unacceptable toxicity.\n\n      ARM B: Patients receive azacitidine PO on days 1-21 and entinostat PO on days 3 and 10.\n      Treatment repeats every 28 days for 2 courses in the absence of disease progression or\n      unacceptable toxicity. Patients with stable or progressive disease receive chemotherapy of\n      the treating oncologist's choice as in Arm A.\n\n      ARM C: Patients receive chemotherapy of the treating oncologist's choice as in Arm A.\n\n      After completion of treatment, patients are followed up every 3-6 months for 24 months and\n      then yearly thereafter."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have histologically or cytologically proven non-small cell lung cancer;\n             tumor tissue must be available from all patients prior to initiation of protocol\n             therapy, either from original diagnostic biopsy, or biopsy performed prior to\n             initiation of protocol therapy\n\n          -  Patients must have measurable disease, defined as at least one lesion that can be\n             accurately measured in at least one dimension (longest diameter to be recorded for\n             non-nodal lesions and short axis for nodal lesions) as >= 20 mm with conventional\n             techniques or as >= 10 mm with spiral computed tomography (CT) scan, magnetic\n             resonance imaging (MRI), or calipers by clinical exam\n\n          -  Patients must have received one prior therapy, and no more than one prior therapy\n\n          -  Patients with epidermal growth factor receptor (EGFR) mutations in exon 19 or 21 and\n             patients with detected anaplastic lymphoma kinase (ALK) translocation may have had\n             two prior therapies if one was a tyrosine kinase inhibitor specific to their mutation\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Karnofsky >=\n             70%)\n\n          -  Life expectancy of greater than 12 weeks\n\n          -  Leukocytes >= 3,000/mcL\n\n          -  Absolute neutrophil count >= 1,500/mcL\n\n          -  Platelets >= 100,000/mcL\n\n          -  Total bilirubin within normal institutional limits\n\n          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transferase\n             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transferase [SGPT])\n             =< 2.5 X institutional upper limit of normal\n\n          -  Creatinine within normal institutional limits OR creatinine clearance >= 60\n             mL/min/1.73 m^2 for patients with creatinine levels above institutional normal\n\n          -  Women of child-bearing potential and men must agree to use adequate contraception\n             (hormonal or barrier method of birth control; abstinence) prior to study entry and\n             for the duration of study participation; should a woman become pregnant or suspect\n             she is pregnant while she or her partner is participating in this study, she should\n             inform her treating physician immediately\n\n          -  Ability to understand and the willingness to sign a written informed consent document\n\n        Exclusion Criteria:\n\n          -  Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for\n             nitrosoureas or mitomycin C) prior to entering the study or those who have not\n             recovered from adverse events due to agents administered more than 4 weeks earlier\n\n          -  Patients who are receiving any other investigational agents\n\n          -  Patients with uncontrolled brain metastases; patients with brain metastases must have\n             stable neurologic status following local therapy (surgery or radiation) for at least\n             4 weeks, and must be without neurologic dysfunction that would confound the\n             evaluation of neurologic and other adverse events; patients may be treated with\n             steroids as clinically indicated\n\n          -  Patients with liver metastases that replace greater than 30% of the liver parenchyma\n\n          -  History of allergic reactions attributed to compounds of similar chemical or biologic\n             composition to entinostat, azacitidine, mannitol, irinotecan, docetaxel, pemetrexed,\n             or gemcitabine, or other agents used in the study\n\n          -  Uncontrolled inter-current illness including, but not limited to, ongoing or active\n             infection, New York Heart Association (NYHA) class 3-4 congestive heart failure,\n             unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social\n             situations that would limit compliance with study requirements\n\n          -  Pregnant women are excluded from this study; breastfeeding should be discontinued if\n             the mother is treated on this protocol\n\n          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral\n             therapy are ineligible"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "165", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_alias": "NCT01846897", 
            "nct_id": "NCT01935947", 
            "org_study_id": "NCI-2013-00949", 
            "secondary_id": [
                "NCI-2013-00949", 
                "NA_00081948/J1309", 
                "9253", 
                "P30CA006973"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm I (azacitidine, entinostat, chemotherapy)", 
                "description": "Given SC", 
                "intervention_name": "azacitidine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "5-AC", 
                    "5-azacytidine", 
                    "azacytidine", 
                    "Vidaza"
                ]
            }, 
            {
                "arm_group_label": "Arm II (azacitidine, entinostat, chemotherapy)", 
                "description": "Given PO", 
                "intervention_name": "azacitidine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "5-AC", 
                    "5-azacytidine", 
                    "azacytidine", 
                    "Vidaza"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm I (azacitidine, entinostat, chemotherapy)", 
                    "Arm II (azacitidine, entinostat, chemotherapy)"
                ], 
                "description": "Given PO", 
                "intervention_name": "entinostat", 
                "intervention_type": "Drug", 
                "other_name": [
                    "HDAC inhibitor SNDX-275", 
                    "SNDX-275"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm I (azacitidine, entinostat, chemotherapy)", 
                    "Arm II (azacitidine, entinostat, chemotherapy)", 
                    "Arm III (chemotherapy)"
                ], 
                "description": "Given IV", 
                "intervention_name": "irinotecan hydrochloride", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Campto", 
                    "Camptosar", 
                    "CPT-11", 
                    "irinotecan", 
                    "U-101440E"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm I (azacitidine, entinostat, chemotherapy)", 
                    "Arm II (azacitidine, entinostat, chemotherapy)", 
                    "Arm III (chemotherapy)"
                ], 
                "description": "Given IV", 
                "intervention_name": "gemcitabine hydrochloride", 
                "intervention_type": "Drug", 
                "other_name": [
                    "dFdC", 
                    "difluorodeoxycytidine hydrochloride", 
                    "gemcitabine", 
                    "Gemzar"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm I (azacitidine, entinostat, chemotherapy)", 
                    "Arm II (azacitidine, entinostat, chemotherapy)", 
                    "Arm III (chemotherapy)"
                ], 
                "description": "Given IV", 
                "intervention_name": "docetaxel", 
                "intervention_type": "Drug", 
                "other_name": [
                    "RP 56976", 
                    "Taxotere", 
                    "TXT"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm I (azacitidine, entinostat, chemotherapy)", 
                    "Arm II (azacitidine, entinostat, chemotherapy)", 
                    "Arm III (chemotherapy)"
                ], 
                "description": "Given IV", 
                "intervention_name": "pemetrexed disodium", 
                "intervention_type": "Drug", 
                "other_name": [
                    "ALIMTA", 
                    "LY231514", 
                    "MTA"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm I (azacitidine, entinostat, chemotherapy)", 
                    "Arm II (azacitidine, entinostat, chemotherapy)", 
                    "Arm III (chemotherapy)"
                ], 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Azacitidine", 
                "Gemcitabine", 
                "Pemetrexed", 
                "Irinotecan", 
                "Camptothecin", 
                "Docetaxel", 
                "Histone Deacetylase Inhibitors"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 9, 2014", 
        "location": [
            {
                "contact": {
                    "email": "gitlitz@usc.edu", 
                    "last_name": "Barbara J. Gitlitz", 
                    "phone": "323-865-3906"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "University of Southern California/Norris Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Barbara J. Gitlitz", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kbodenhorn@aahs.org", 
                    "last_name": "Peter R. Graze", 
                    "phone": "410-573-5300"
                }, 
                "facility": {
                    "address": {
                        "city": "Annapolis", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21401"
                    }, 
                    "name": "Anne Arundel Medical Center"
                }, 
                "investigator": {
                    "last_name": "Peter R. Graze", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mtang@gbmc.org", 
                    "last_name": "Mei Tang", 
                    "phone": "443-849-3051"
                }, 
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21204"
                    }, 
                    "name": "Greater Baltimore Medical Center"
                }, 
                "investigator": {
                    "last_name": "Mei Tang", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "pdennis@nih.gov", 
                    "last_name": "Phillip A. Dennis", 
                    "phone": "410-550-9250"
                }, 
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21224"
                    }, 
                    "name": "Johns Hopkins Bayview Medical Center"
                }, 
                "investigator": {
                    "last_name": "Phillip A. Dennis", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "brahmju@jhmi.edu", 
                    "last_name": "Julie R. Brahmer", 
                    "phone": "410-502-7159"
                }, 
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }, 
                    "name": "Johns Hopkins University/Sidney Kimmel Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Julie R. Brahmer", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized Phase II Trial of Cytotoxic Chemotherapy With or Without Epigenetic Priming in Patients With Advanced Non-Small Cell Lung Cancer", 
        "overall_official": {
            "affiliation": "Johns Hopkins University/Sidney Kimmel Cancer Center", 
            "last_name": "Julie Brahmer", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The final analysis will be by Fisher's Exact test, with percentage of patients who have not progressed as the outcome variable. Using Fisher's Exact test for analysis with 55 patients per treatment group will provide 88% power to detect an increase from 40% (chemotherapy alone) to 65% (epigenetic therapy followed by chemotherapy) in the number of patients who are progression free at six months.", 
            "measure": "Percentage of patients progression-free at 6 months from the time of randomization", 
            "safety_issue": "No", 
            "time_frame": "At 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01935947"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Progression-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "From the time of randomization until radiologic or clinical progression is noted, assessed up to 2 years"
            }, 
            {
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "From the time of enrollment to trial until death, assessed up to 2 years"
            }
        ], 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}